Clinical Trial Update: TACE Combined With Penpulimab and Anlotinib for Advanced HCC [Phase 2, Phase 3]

View source ↗

Summary

Phase 2/3 trial evaluating TACE with penpulimab and anlotinib for advanced hepatocellular carcinoma is ongoing with unknown status.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Anlotinib (anlotinib)
• Penpulimab
• TACE

Snippet

Sponsor: Zhongda Hospital | Conditions: Hepatocellular Carcinoma | Phase 2, Phase 3 | Status: UNKNOWN